12/09/2025
I try not to get too hype for new meds, but Retatrutide has my attention. .bloodsugar.rd
Most GLP-1 medications can’t directly target the liver because the liver has no GLP-1 receptors. But it’s rich in glucagon receptors.
Retatrutide is the first triple agonist (GLP-1 + GIP + glucagon), which means it CAN directly reduce liver fat.
The Phase 2 trial showed 86% reduction in hepatic fat content.
This is huge because 5-7% of people with type 2 diabetes develop fatty liver disease and fibrosis. Until now, we could only help indirectly through weight loss.
Other impressive results:
• 24.2% mean weight loss at 48 weeks (highest we’ve seen)
• 2.02% A1c reduction in people with type 2 diabetes
• 77-82% of participants reached A1c ≤6.5%
• Improvements in blood pressure, cholesterol, and inflammation
Timeline: Phase 3 trials ongoing, FDA approval likely 2026-2027.
I wrote a comprehensive breakdown on my blog covering the mechanism of action, trial data, side effects, cost considerations, and who might benefit most.
Comment “Retatrutide” and I can send you the link to that blog.
Questions about triple agonists? Drop them below 👇
